Heidi V. Russell

4.8k citations

74 papers · 3.5k indexed · 2 hit papers · h-index 23

Oncology top 1%
Immunology top 2%
Molecular Biology top 10%
Genetics top 2%
Neurology top 2%

Co-authors: Malcolm K. Brenner Helen E. Heslop Adrian P. Gee Cliona M. Rooney Zhuyong Mei Enli Liu Claudia Rössig Gary D. Myers
Topics: Neuroblastoma Research and Treatments (30 papers)Childhood Cancer Survivors' Quality of Life (12 papers)Cancer, Hypoxia, and Metabolism (10 papers)
Cited by: Oncology Immunology Neurology
Journals: Nature Medicine Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: United States United Kingdom Canada

In The Last Decade

Heidi V. Russell

71 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

2008 919 citations Heidi V. Russell et al. profile →
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

2011 882 citations Chrystal U. Louis, Heidi V. Russell et al. profile →

Peers

Countries citing papers authored by Heidi V. Russell

Since Specialization

Citations

This map shows the geographic impact of Heidi V. Russell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi V. Russell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi V. Russell more than expected).

Fields of papers citing papers by Heidi V. Russell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi V. Russell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi V. Russell. The network helps show where Heidi V. Russell may publish in the future.

Co-authorship network of co-authors of Heidi V. Russell

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi V. Russell. A scholar is included among the top collaborators of Heidi V. Russell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi V. Russell. Heidi V. Russell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Salvage Therapy Efficacy is Modified by Risk Group at Diagnosis in Patients With Relapsed Rhabdomyosarcoma 2024 ·Pediatric Blood & Cancer ·(unknown),Abha A. Gupta,Bhuvana A. Setty,Mary Frances Wedekind,Jeremy M. Schraw,Philip J. Lupo,Heidi V. Russell,(unknown),David Walterhouse,Douglas S. Hawkins,(unknown)	0
2	Teaching and Safety-Net Hospital Penalization in the Hospital-Acquired Condition Reduction Program 2024 ·JAMA Network Open ·José A. Serpa,(unknown),César A. Arias,Robert O. Morgan,Heidi V. Russell,Hongyu Miao,(unknown)	2
3	Death anxiety predicts fear of Cancer recurrence and progression in ovarian Cancer patients over and above other cognitive factors 2023 ·Journal of Behavioral Medicine ·(unknown),Louise Sharpe,Heidi V. Russell	8
4	Cost-effectiveness frameworks for comparing genome and exome sequencing versus conventional diagnostic pathways: A scoping review and recommended methods 2022 ·Genetics in Medicine ·Bart S. Ferket,(unknown),(unknown),Akila Pai,Kathleen F. Mittendorf,Heidi V. Russell,Flavia Chen,Frances L. Lynch,Kristen Hassmiller Lich,Lucia A. Hindorff,Renate Savich,Anne Slavotinek,Hadley Stevens Smith,Bruce D. Gelb,David L. Veenstra	9
5	A safety and feasibility trial of ¹³¹I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study 2021 ·Pediatric Blood & Cancer ·Brian Weiss,Gregory A. Yanik,Arlene Naranjo,Fan F. Zhang,Wendy Fitzgerald,Barry L. Shulkin,Marguerite T. Parisi,Heidi V. Russell,Stephan A. Grupp,Luke Pater,Peter Mattei,Yaël P. Mossé,Hollie Lai,Jason A. Jarzembowski,Hiroyuki Shimada,Judith G. Villablanca,Roger Giller,Rochelle Bagatell,Julie R. Park,Katherine K. Matthay	23
6	US private payers’ perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER) 2021 ·Genetics in Medicine ·Kathryn A. Phillips,Julia R. Trosman,Michael P. Douglas,Bruce D. Gelb,Bart S. Ferket,Lucia A. Hindorff,Anne Slavotinek,Jonathan S. Berg,Heidi V. Russell,Beth Devine,(unknown),Hadley Stevens Smith	8
7	Is high‐risk neuroblastoma induction chemotherapy possible without G‐CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors 2020 ·Pediatric Blood & Cancer ·Sarah Burkhead Whittle,Valeria Smith,Allison Silverstein,(unknown),Charles G. Minard,M. Brooke Bernhardt,Peter E. Zage,Rajkumar Venkatramani,Jed G. Nuchtern,Andras Heczey,Heidi V. Russell,Jason M. Shohet,Jennifer H. Foster	3
8	Exome sequencing compared with standard genetic tests for critically ill infants with suspected genetic conditions 2020 ·Genetics in Medicine ·Hadley Stevens Smith,J. Michael Swint,Seema R. Lalani,Marcia C. de Oliveira Otto,José‐Miguel Yamal,Heidi V. Russell,Brendan Lee	26
9	Blood product administration during high risk neuroblastoma therapy 2019 ·Pediatric Hematology and Oncology ·Allison Silverstein,(unknown),Valeria Smith,Jennifer H. Foster,Heidi V. Russell,Sarah Burkhead Whittle	3
10	Using the Delphi method to identify clinicians’ perceived importance of pediatric exome sequencing results 2019 ·Genetics in Medicine ·Hadley Stevens Smith,Heidi V. Russell,Brendan Lee,Stephanie R. Morain	11
11	Emergency Department Visits by Adolescent and Young Adult Cancer Patients Compared with Pediatric Cancer Patients in the United States 2018 ·Journal of Adolescent and Young Adult Oncology ·Sapna Kaul,Heidi V. Russell,J. Andrew Livingston,Anne C. Kirchhoff,Daniel C. Jupiter	5
12	Clinical Application of Genome and Exome Sequencing as a Diagnostic Tool for Pediatric Patients: a Scoping Review of the Literature 2018 ·Genetics in Medicine ·Hadley Stevens Smith,J. Michael Swint,Seema R. Lalani,José‐Miguel Yamal,Marcia C. de Oliveira Otto,(unknown),Amy Taylor,Brendan Lee,Heidi V. Russell	86
13	Radiation Therapy to the Primary and Postinduction Chemotherapy MIBG-Avid Sites in High-Risk Neuroblastoma 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Ali Mazloom,Chrystal U. Louis,Jed G. Nuchtern,Eugene S. Kim,Heidi V. Russell,Wendy Allen‐Rhoades,Robert A. Krance,Arnold C. Paulino	35
14	A phase I study of zoledronic acid and low‐dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study 2010 ·Pediatric Blood & Cancer ·Heidi V. Russell,Susan Groshen,Tasnim Ara,Yves A. DeClerck,(unknown),Hollie Jackson,Heike E. Daldrup‐Link,Araz Marachelian,Andrej Skerjanec,Julie R. Park,Howard M. Katzenstein,Katherine K. Matthay,Susan M. Blaney,Judith G. Villablanca	39
15	Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma 2009 ·Molecular Cancer Therapeutics ·Xiaoying Shang,Susan M. Burlingame,M. Fatih Okcu,Ningling Ge,Heidi V. Russell,Rachel A. Egler,(unknown),Sanjeev A. Vasudevan,Jianhua Yang,Jed G. Nuchtern	79
16	Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma 2009 ·Molecular Cancer Therapeutics ·Sanjeev A. Vasudevan,(unknown),(unknown),Ningling Ge,(unknown),Heidi V. Russell,John Hicks,Andrew D. Ludwig,(unknown),Susan M. Burlingame,Eugene S. Kim,Javed Khan,Jianhua Yang,Jed G. Nuchtern	10
17	Infantile fibrosarcoma: Clinical and histologic responses to cytotoxic chemotherapy 2009 ·Pediatric Blood & Cancer ·Heidi V. Russell,John Hicks,Alison A. Bertuch,Murali Chintagumpala	27
18	Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells 2008 ·Cancer Research ·Tasnim Ara,Liping Song,Hiroyuki Shimada,Nino Keshelava,Heidi V. Russell,Leonid S. Metelitsa,Susan Groshen,Robert C. Seeger,Yves A. DeClerck	145
19	Diagnostic and therapeutic role of endoscopic retrograde cholangiopancreatography in biliary rhabdomyosarcoma 2008 ·World Journal of Gastroenterology ·Ryan Himes,Isaac Raijman,Milton J. Finegold,Heidi V. Russell,Douglas S. Fishman	8
20	Reconstruction of biological networks through gene silencing and overexpression 2007 ·Open Repository and Bibliography (University of Luxembourg) ·Heidi V. Russell,Jorge Gonçalves,Douglas M. Neil,(unknown)	2

About Heidi V. Russell

Heidi V. Russell is a scholar working on Neurology, Speech and Hearing and Cancer Research, having authored 74 papers that have together received 3.5k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (30 papers), Childhood Cancer Survivors' Quality of Life (12 papers) and Cancer, Hypoxia, and Metabolism (10 papers). The work is most often cited by research in Oncology (2.3k citations), Immunology (1.1k citations) and Neurology (714 citations). Heidi V. Russell has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Malcolm K. Brenner, Helen E. Heslop, Adrian P. Gee, Cliona M. Rooney, Zhuyong Mei, Enli Liu, Claudia Rössig, Gary D. Myers, Barbara Savoldo and Gianpietro Dotti. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact